On 1 January 2014 new conditions relating to the prescribing and dispensing of Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate) came into effect.Read More >>
The Australian Packaging Covenant is a voluntary initiative by Government and Industry to reduce the environmental effects of packaging. It is designed to minimise the environmental impacts arising from the disposal of used packaging, conserve resources through better design and production processes and facilitate the re-use and recycling of used packaging materials. Here you can view Aspen Australia's plan and report.Read More >>
Please click on the 'Read full article' link below for an update on the current situation with Di-gesic and Doloxene.Read More >>
Aspen Australia (Aspen) wishes to advise that it is unexpectedly out of stock of Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg).Read More >>
The Australian competition authorities have approved Aspen's acquisition of the Australian IN business and the transaction will be effective in Australia from 28 April 2013.Read More >>
On 5th April, 2013 the Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.Read More >>
Di-Gesic and Doloxene continue to be registered on the Australian Register of Therapeutic Goods (ARTG) and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.Read More >>
Aspen will continue to appeal the Therapeutic Goods Administrationâ€Ÿs decision to de-register Di-Gesic and Doloxene.
The TGA has affirmed its decision to cancel the registration of DPP products, however its decision will not take effect until further order of the AAT. Aspen remains concerned to ensure that patients are not left without adequate pain relief, and considers that this is likely to be the case if Di-Gesic and Doloxene are de-registered. Consequently, Aspen will continue its appeal.
Di-Gesic and Doloxene will remain on the register while Aspenâ€Ÿs appeal is heard and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.Read More >>